<DOC>
	<DOCNO>NCT00265915</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving rituximab together GM-CSF may effective treatment chronic lymphocytic leukemia . PURPOSE : This phase II trial study well give rituximab together GM-CSF work treat patient B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Rituximab GM-CSF Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete overall response rate patient B-cell chronic lymphocytic leukemia treat rituximab sargramostim ( GM-CSF ) . - Determine time progression patient treat regimen . - Determine effect regimen CD20 antigen expression soluble CD20 level patient . OUTLINE : This parallel-group , multicenter study . Patients stratify accord disease status Patients receive rituximab IV day 4 , 11 , 18 , 25 sargramostim ( GM-CSF ) subcutaneously day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 , 29 , 31 , 33 , 36 , 38 , 40 , 43 , 45 , 47 , 50 , 52 , 54 ( course 1 ) . Patients respond disease may receive additional course treatment . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 130 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia meeting 1 follow criterion : Previously treat stage III IV earlier stage disease evidence active disease , define ≥ 1 following : Weight loss &gt; 10 % within past 6 month Extreme fatigue Fever night sweat without evidence infection Worsening anemia thrombocytopenia Progressive lymphocytosis rapid lymphocyte double time Marked hypogammaglobulinemia paraproteinemia Lymphadenopathy &gt; 5 cm diameter Previously untreated stage 0II disease symptom significant fatigue high risk progression due B2 microglobulin &gt; 3.0 mg/mL Patients ≥ 70 year age previously untreated stage III IV earlier stage disease require treatment refuse chemotherapy eligible PATIENT CHARACTERISTICS : Performance status Zubrod 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin &lt; 2.0 mg/dL* ( elevated bilirubin allow due Gilbert 's disease ) NOTE : *Liver dysfunction due lymphocytic organ infiltration allow Renal Creatinine &lt; 2.5 mg/dL* NOTE : *Renal dysfunction due lymphocytic organ infiltration allow Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active viral infection ( e.g. , viral hepatitis ) PRIOR CONCURRENT THERAPY : Chemotherapy See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>